Nursing care
Cannabis and Synthetic Cannabinoids nursing care: what to assess and what to do first
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Cannabis intoxication causes relaxation, tachycardia, red eyes, and increased appetite; synthetic cannabinoids can instead cause severe agitation, psychosis, and seizures, and they will not show up on a standard urine drug screen. Treat any patient with an unexplained psychotic or seizure presentation and a history of vaping or smoking an unknown substance as a possible synthetic cannabinoid exposure until proven otherwise.
Recognising it at the bedside
Cannabis intoxication has a recognisable pattern: conjunctival injection, tachycardia, dry mouth, increased appetite, slowed reaction time, and a generally relaxed or euphoric affect. Vital signs move modestly and the patient is usually redirectable.
Synthetic cannabinoids, sold as 'Spice' or 'K2' among other names, mimic none of that reliably. Expect severe agitation, paranoia, hallucinations, and combative behaviour out of proportion to anything cannabis produces. Tachycardia can be marked, blood pressure can spike, and seizures occur in a meaningful minority of presentations. The patient may report smoking or vaping 'weed' while showing a clinical picture that looks nothing like cannabis toxicity, because the product is not cannabis at all, only marketed alongside it.
Why the classic presentation misleads
A nurse anchored on 'patient smoked marijuana, expect drowsiness and munchies' will miss a synthetic cannabinoid emergency. These compounds bind the same cannabinoid receptors far more potently and with less predictable effect, producing agitation, psychosis, and seizure activity that the plant compound essentially does not cause at typical recreational doses.
The history given by the patient or bystanders often reinforces the wrong assumption, since synthetic products are frequently sold and described as cannabis, incense, or herbal blends. The mismatch between a benign-sounding history and a severe presentation, hallucinating, seizing, or acutely psychotic, is itself the clinical clue. Do not let the reported substance override what the patient is actually doing in front of you.
Priority nursing actions
Airway and seizure precautions come first for any patient with altered mental status or a seizure history in this presentation: side rails padded, suction available, and oxygen ready. For severe agitation, prioritise a low-stimulation environment and de-escalation before reaching for chemical or physical restraint, since anxiety and paranoia from synthetic cannabinoids feed on overstimulation.
Monitor cardiac status closely, tachycardia and hypertension can be significant, and obtain continuous cardiac monitoring if agitation or vital sign instability persists. Reorient the patient frequently and communicate clearly and calmly, since psychotic symptoms respond poorly to confrontation. Notify the provider promptly if seizure activity, chest pain, or worsening mental status develops, and document the substance history exactly as the patient or bystander reported it, including product names if known.
Labs and diagnostics to expect
Expect the standard urine drug screen to come back negative for cannabinoids even when the patient has clearly used a synthetic product, because these screens test for THC metabolites specifically and most synthetic compounds are chemically distinct enough to evade detection. A negative screen does not rule out synthetic cannabinoid use; it is, if anything, consistent with it given a matching clinical picture.
Basic labs still matter: electrolytes and renal function to assess for rhabdomyolysis in a prolonged agitated or seizing patient, cardiac monitoring or ECG if tachycardia or chest symptoms are present, and a creatine kinase level if sustained muscle activity or restraint use raises concern. Specialised synthetic cannabinoid testing exists but is not routinely available in most emergency or acute settings, so clinical suspicion, not a lab result, drives the diagnosis.
Complications and their early signs
Watch for status epilepticus in a patient whose seizure activity does not self-terminate quickly; synthetic cannabinoid seizures can recur and cluster. Acute psychosis can persist well beyond the expected intoxication window, and some patients go on to a more prolonged psychotic episode requiring psychiatric evaluation rather than simple observation.
Rhabdomyolysis is a real risk after prolonged agitation, seizure, or physical restraint, so watch for dark urine, rising creatine kinase, and declining urine output. Hyperthermia can accompany severe agitation and needs active cooling measures if temperature climbs. Cardiac complications, including arrhythmia from marked tachycardia, warrant continued monitoring until the patient is clinically stable and vital signs have normalised.
Teaching that changes outcomes
Teach patients and families explicitly that synthetic cannabinoids are not a stronger or legal version of marijuana; they are a different class of chemical with unpredictable potency, since manufacturers vary the compound and dose from batch to batch. The same product name can contain a completely different substance from one purchase to the next.
Reinforce that a negative drug screen does not mean the substance was safe or that it wasn't the cause of symptoms, a point patients often use to argue against having used anything at all. For patients with recurrent use, discuss the specific risks seen on this admission, seizure, psychosis, or cardiac strain, rather than a generic warning about drug use, and refer to substance use services before discharge.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our mental health practice questions are the closest set to what this page covers.
Common questions
Will a urine drug screen detect synthetic cannabinoids?
No, not on a standard panel. Standard screens test for THC metabolites from natural cannabis, and most synthetic cannabinoid compounds are structurally different enough to return a negative result even with confirmed use.
What's the biggest clinical difference between cannabis and synthetic cannabinoid toxicity?
Cannabis typically causes relaxation, tachycardia, and increased appetite with a redirectable patient. Synthetic cannabinoids can cause severe agitation, psychosis, and seizures that cannabis itself does not produce.
Should a negative drug screen change your suspicion of synthetic cannabinoid use?
No. A negative screen is expected with synthetic cannabinoid use and should not lower your suspicion if the clinical picture, agitation, hallucinations, or seizure, fits.
What is the priority nursing action for a severely agitated patient suspected of synthetic cannabinoid use?
Ensure a safe, low-stimulation environment and attempt de-escalation while preparing for seizure precautions and continuous cardiac monitoring. Physical or chemical restraint is a later step, not the first response.
More on mental health